United Arab Emirates (UAE) Biobanking Market Overview, 2029

The collection, storing, and sharing of biological specimens and related data is known as biobanking, and it is a fundamental component of contemporary medical research. It is an important instrument for scientific investigation that helps scientists understand the nuances of human health and illness. Advancement in technology had rise of personalized medicine, and the increasing recognition of the significance of data at a large size, analysis in healthcare innovation have all contributed to the global rise in biobanking in the past few years. The global need for personalized healthcare and the increasing field of biomedical study have propelled the biobanking market's strong expansion.

The amalgamation of biobanking with modern technologies like blockchain and artificial intelligence has rapidly transformed security of information and sample administration. There is a rising movement to create networks of collaboration and disease-specific biobanks in order to speed up research and ease data exchange. These advancements highlight how active the biobanking industry is and how crucial a role it will play in determining the direction of healthcare. The biobanking industry in the United Arab Emirates (UAE) is expanding quickly due to a deliberate goal to position the nation as a pioneer in healthcare innovation.

The United Arab Emirates is seeking to establish itself as a center for biomedical research in the Middle East by large investments in research infrastructure and partnerships with foreign partners. The reason behind the growth are campaigns to raise public awareness and encourage participation in biobanking activities, which is creating the foundation for a thriving research ecosystem. The UAE biobanking market is still developing and confronts a number of obstacles along the way. The regulatory frameworks that oversee biobanking processes require additional refinement to guarantee adherence to global norms, while also taking into account cultural and ethical peculiarities specific to the area.

In addition, there is a need for increased cooperation between government, business, and academia in order to maximise resource use and improve research results. Furthermore, in order to maximise the effect of biobanking programmes and promote scientific discovery, it is imperative to cultivate a culture of data sharing and openness. In order to realise the full potential of biobanking in the UAE and promote healthcare innovation in the area, it will be imperative to overcome these obstacles.

According to the research report, the UAE Biobanking market was valued at more than USD 110 Million in 2023. The biobanking industry in the United Arab Emirates (UAE) has advanced significantly in the past few years, as evidenced by the construction of cutting-edge facilities and strategic partnerships meant to promote biomedical research and healthcare innovation. Important advancements include the opening of state-of-the-art biobanks with sophisticated retrieving and storage facilities in major cities like Abu Dhabi and Dubai, which guarantee the preservation of superior biological samples.

Authorities, educational institutions, and healthcare providers have worked together to create cooperative projects that have made it easier to gather, preserve, and use a variety of biological specimens for clinical and research purposes. These breakthroughs demonstrate the UAE's dedication to being the region's preeminent centre for biobanking and medical research, advancing the fields of genomics, personalised medicine, and healthcare delivery.

Lab information systems, equipment, and consumables are examples of products that are the basis for segmentation in the United Arab Emirates. apparatus necessary for various biobanking stages. To preserve biological samples over time and guarantee their integrity for use in future research, ultra-low temperature freezers are essential. Accuracy and efficiency are increased in sample preparation by using automated systems, like liquid handling robots and centrifuges. Licensing and sample management systems, such as LIMS software and barcode scanners, allow for accurate sample organization and identification.

Scientific instruments that enable sophisticated examination of biological materials, such as mass spectrometers and high-throughput sequencers, produce significant research data. Items that are used once and are disposed of during regular biobanking operations are considered consumables. Standardized and safe sample collection is made possible by the essential instruments included in sample collection kits, such as tissue biopsy kits and blood collection tubes.

The major service of biobanks, which involves the collection, processing, storage, and management of biological samples and associated data. In UAE biobanks offer several solutions for maintaining diverse sample collections, including blood, tissues, cells, and DNA, along with clinical and demographic information. These repositories serve as valuable resources for researchers, clinicians, and pharmaceutical companies conducting biomedical research and developing new therapies. Validation and qualification services ensure the quality, integrity, and regulatory compliance of biological samples and biobanking processes.

UAE biobanks provide validation and qualification services to verify the accuracy, reliability, and traceability of samples, equipment, and procedures. This includes validation of sample storage conditions, equipment performance, and data management systems, as well as qualification of personnel and facilities according to international standards and regulatory requirements. Lab processing services involve sample preparation, analysis, and characterization to generate research data and clinical insights.

Biobanks in the UAE offer a range of lab processing services, including sample processing, nucleic acid extraction, histological analysis, and omics technologies. Cold chain logistics services ensure the safety and secure transportation of biological samples under controlled temperature conditions. In UAE biobanks provide specialized cold chain logistics solutions to maintain sample integrity during transportation from collection sites to storage facilities and between research institutions.

There are 2 types of Biobank, firstly, Physical biobanks are establishments that preserve biological samples in palpable forms, like tissues, blood, cells, and DNA, under carefully monitored circumstances. These biobanks keep large collections of samples from patients, populations, and individuals as well as related clinical and demographic information.

Virtual biobanks, sometimes referred to as registry-based biobanks or data-driven biobanks, are electronic or digital repositories of biological sample and related data. Virtual biobanks maintain databases or registries with genetic information, other clinical or phenotypic data collected from individuals or patient cohorts, and anonymized or de-identified health information instead of physically storing specimens.

Biobanks in the UAE play a crucial role in drug discovery and clinical research by providing researchers with access to a wide range of biological samples for studying disease mechanisms, identifying therapeutic targets, and evaluating drug candidates. Researchers utilize samples from biobanks to conduct preclinical studies, screen for potential drug candidates, and assess drug efficacy and safety in clinical trials. Biobanking supports translational research efforts by facilitating the transition of discoveries from the laboratory to clinical applications.

Biobanks contribute to therapeutics development by providing researchers and pharmaceutical companies with access to well-characterized biological samples for developing new therapies and personalized treatment approaches. Biobanks play a role in clinical diagnostics by providing healthcare providers with access to biological samples and associated data for diagnostic testing and disease monitoring. Samples from biobanks are used to develop diagnostic assays, validate biomarkers, and improve disease detection and prognostication.

Years considered in this report:

• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in the report:

• Biobanking market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendations

By Product Type:

• Equipment
• Consumables
• Laboratory Information Systems

By Service Type:

• Biobanking and Repository
• Validation/Qualification
• Lab Processing
• Cold Chain Logistic
• Others

By Biospecimen Type:

• Human Tissues
• Stem Cells
• Organs
• Others

By Biobank:

• Physical Biobanks
• Virtual Biobanks

By Application:

• Drug Discovery and Clinical Research
• Therapeutics
• Clinical Diagnostics
• Others

By Type of Biobank:

• Population-based Biobanks
• Disease-oriented Biobanks

By Ownership:

• National/regional agency
• Non-Profit Organization
• Universities
• Private Organization

By Storage:

• Manual Storage
• Automated Storage

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases.

After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. After this, the analysts made primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once they acquired the primary data, they started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Biobanking industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.